Cross-species metabolic characterization of eutylone and mechanism-based inhibition of CYP2D6 and CYP2B6 with drug interaction implications

, without any measurable inhibition of UGT enzymes. This mechanism-based inhibition, comparable in efficiency to that reported for MDMA, suggests a clinically relevant potential to increase exposure to co-used CYP2D6 and CYP2B6 substrates. Together, these findings provide a translationally relevant metabolic framework for eutylone, highlight critical rat-human differences, and identify interaction-driven risks that are particularly relative in the current landscape of polydrug misuse.